Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.47), $0.16 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $71.09 million versus the consensus estimate of $63.79 million.

Guidance:

"Ongoing operating expenses for 2018 are now expected to approximate $395 to $420 million, inclusive of an increase to $58 million of share-based compensation expense, which compares to the prior operating expense guidance of $365 to $395 million. The increase from prior guidance is largely driven by the announced commercial expansion, first quarter 2018 milestone payment to BIAL for opicapone, and increase in share-based compensation."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.